Descriptor English: | Brimonidine Tartrate | ||||
Descriptor Spanish: |
Tartrato de Brimonidina
| ||||
Descriptor Portuguese: | Tartarato de Brimonidina | ||||
Descriptor French: | Tartrate de brimonidine | ||||
Entry term(s): |
5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate 5-bromo-6-(imidazolidinylideneamino)quinoxaline 5-bromo-6-(imidazolin-2-ylamino)quinoxaline AGN 190342 AGN-190342 AGN190342 Alphagan Alphagan P Brimonidine Brimonidine Purite Brimonidine Tartrate (1:1) Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer Brimonidine Tartrate, (R-(R*,R*))-Isomer Bromoxidine Mirvaso Ratio Brimonidine Ratio-Brimonidine Sanrosa UK 14,304 UK 14,304 18 UK 14,304-18 UK 14,30418 UK 14,308 UK 14304 UK 14308 UK-14,304-18 UK-14,308 UK-14304 UK14,30418 UK14,308 UK14304 |
||||
Tree number(s): |
D03.633.100.857.070 |
||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D000068438 | ||||
Scope note: | A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. |
||||
Allowable Qualifiers: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis EC economics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||
Pharm Action: |
Antihypertensive Agents Antihipertensivos Anti-Hipertensivos Antihypertenseurs antihipertensivos Adrenergic alpha-2 Receptor Agonists Agonistas de Receptores Adrenérgicos alfa 2 Agonistas de Receptores Adrenérgicos alfa 2 Agonistes des récepteurs alpha-2 adrénergiques agonistas de receptores adrenérgicos alfa-2 |
||||
Registry Number: | 4S9CL2DY2H | ||||
CAS Type 1 Name: | 6-quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) | ||||
Public MeSH Note: | 2016; BRIMONIDINE TARTRATE was indexed under QUINOXALINES 1980-2015, and under IMIDAZOLES 1978-1980 |
||||
History Note: | 2016 (1978) |
||||
DeCS ID: | 55937 | ||||
Unique ID: | D000068438 | ||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||
Date Established: | 2016/01/01 | ||||
Date of Entry: | 2015/07/01 | ||||
Revision Date: | 2018/05/21 |
-
-
CHEMICALS AND DRUGS
Heterocyclic Compounds [D03]Heterocyclic Compounds
|
Brimonidine Tartrate
- Preferred
Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer
- Narrower
Brimonidine Purite
- Narrower
AGN 190342
- Narrower
Sanrosa
- Narrower
Alphagan
- Narrower
Brimonidine
- Broader
Alphagan P
- Narrower
UK 14,304
- Narrower
Ratio-Brimonidine
- Narrower
UK 14,304-18
- Narrower
UK 14308
- Narrower
Brimonidine Tartrate, (R-(R*,R*))-Isomer
- Narrower
Brimonidine Tartrate (1:1)
- Narrower
Mirvaso
- Narrower
Concept UI |
M0065049 |
Scope note | A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. |
Preferred term | Brimonidine Tartrate |
Entry term(s) |
5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate |
Concept UI |
M0312903 |
Preferred term | Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer |
Concept UI |
M0517501 |
Preferred term | Brimonidine Purite |
Concept UI |
M0065040 |
Preferred term | AGN 190342 |
Entry term(s) |
AGN-190342 AGN190342 |
Concept UI |
M000603526 |
Preferred term | Sanrosa |
Concept UI |
M000603394 |
Preferred term | Alphagan |
Concept UI |
M000603395 |
Preferred term | Brimonidine |
Entry term(s) |
5-bromo-6-(imidazolidinylideneamino)quinoxaline 5-bromo-6-(imidazolin-2-ylamino)quinoxaline Bromoxidine |
Concept UI |
M000638382 |
Preferred term | Alphagan P |
Concept UI |
M0065042 |
Preferred term | UK 14,304 |
Entry term(s) |
UK 14304 UK-14304 UK14304 |
Concept UI |
M000603399 |
Preferred term | Ratio-Brimonidine |
Entry term(s) |
Ratio Brimonidine |
Concept UI |
M0065043 |
Preferred term | UK 14,304-18 |
Entry term(s) |
UK 14,304 18 UK 14,30418 UK-14,304-18 UK14,30418 |
Concept UI |
M0065045 |
Preferred term | UK 14308 |
Entry term(s) |
UK 14,308 UK-14,308 UK14,308 |
Concept UI |
M0312901 |
Preferred term | Brimonidine Tartrate, (R-(R*,R*))-Isomer |
Concept UI |
M0312902 |
Preferred term | Brimonidine Tartrate (1:1) |
Concept UI |
M000603397 |
Preferred term | Mirvaso |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey